

# Histamine H1 receptor antagonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/HB749D7580D4EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: HB749D7580D4EN

## Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Histamine H1 Receptor Antagonists - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Histamine H1 Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Histamine H1 Receptor Antagonists Understanding

#### Histamine H1 Receptor Antagonists: Overview

Histamine and its receptors (H1R–H4R) play a crucial and significant role in the development of various allergic diseases. H1R are expressed in many cells, including mast cells, and are involved in Type 1 hypersensitivity reactions. Activation of the H1 receptor increases vascular permeability, stimulates sensory nerves of airways, and promotes chemotaxis of eosinophils, so can cause sneezing, nasal congestion and rhinorrhea. The H1 receptor is widely distributed in the periphery, notably smooth muscle, where it stimulates contraction (vasoconstriction). It is also found in the adrenal medulla, vascular endothelium and heart and throughout the CNS, including the

cerebral cortex, spinal cord and cerebellum. H1R-antagonists act as highly effective inverse agonists of H1R, which reduce basal activity of the receptor and therefore are expected to interfere with the key molecular switches involved in the GPCR activation mechanism.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Histamine H1 Receptor Antagonists R&D. The therapies under development are focused on novel approaches for Histamine H1 Receptor Antagonists.

## Histamine H1 Receptor Antagonists Emerging Drugs Chapters

This segment of the Histamine H1 Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Histamine H1 Receptor Antagonists Emerging Drugs

### TNX-102 SL: Tonix Pharmaceuticals

TNX-102 is a multifunctional agent including antagonism of 5-HT<sub>2A</sub>,  $\alpha$ <sub>1</sub>-adrenergic and histamine H1 receptors. TNX-102 SL is a small, rapidly-disintegrating, sublingual product candidate containing 2.8 mg of cyclobenzaprine HCl. The unique formulation has been designed to optimize the delivery and absorption of cyclobenzaprine for the therapeutic benefit of improving sleep quality, while minimizing the potential residual effects of oral formulations of cyclobenzaprine. The drug is in phase III clinical studies for the treatment of fibromyalgia and in Phase II studies for agitation and alcohol use disorder.

### Flunarizine: Xenon Pharmaceuticals

Flunarizine is a selective calcium entry blocker with calmodulin binding properties and

histamine H1 blocking activity. The drug is being studied for the treatment-resistant childhood absence epilepsy (CAE) and potentially other neurological disorders.

Further product details are provided in the report.....

## Histamine H1 Receptor Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Histamine H1 Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players working on Histamine H1 Receptor Antagonists

There are approx. 15+ key companies which are developing the Histamine H1 Receptor Antagonists. The companies which have their Histamine H1 Receptor Antagonists drug candidates in the most advanced stage, i.e. Phase III include, Tonix Pharmaceuticals.

### Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Histamine H1 Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been

categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

## Histamine H1 Receptor Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Histamine H1 Receptor Antagonists therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Histamine H1 Receptor Antagonists drugs.

## Histamine H1 Receptor Antagonists Report Insights

Histamine H1 Receptor Antagonists Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Histamine H1 Receptor Antagonists Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

## Current Scenario and Emerging Therapies:

How many companies are developing Histamine H1 Receptor Antagonists drugs?

How many Histamine H1 Receptor Antagonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Histamine H1 Receptor Antagonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Histamine H1 Receptor Antagonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Histamine H1 Receptor Antagonists and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Otsuka Pharmaceutical

Tonix Pharmaceuticals

Gedeon Richter

JDP Therapeutics

Xenon Pharmaceuticals

FAES Farma

Hyundai Pharmaceutical

Lohmann Therapie-Systeme

Akari Therapeutics

### Key Products

Aripiprazole

TNX-102 SL

Cariprazine

JDP-205

Flunarizine

Bilastine

HDDO-1801

Asenapine transdermal patch

Votucalis

## Contents

Introduction

Executive Summary

Histamine H1 Receptor Antagonists: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Histamine H1 Receptor Antagonists – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Histamine H1 Receptor Antagonists companies' collaborations, Licensing, Acquisition  
-Deal Value Trends

Histamine H1 Receptor Antagonists Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

TNX-102 SL: Tonix Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Flunarizine: Xenon Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description



Research and Development  
Product Development Activities  
Drug profiles in the detailed report.....  
Pre-clinical and Discovery Stage Products  
Comparative Analysis  
Votucalis: Akari Therapeutics  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report.....  
Inactive Products  
Comparative Analysis  
Histamine H1 Receptor Antagonists Key Companies  
Histamine H1 Receptor Antagonists Key Products  
Histamine H1 Receptor Antagonists- Unmet Needs  
Histamine H1 Receptor Antagonists- Market Drivers and Barriers  
Histamine H1 Receptor Antagonists- Future Perspectives and Conclusion  
Histamine H1 Receptor Antagonists Analyst Views  
Histamine H1 Receptor Antagonists Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Histamine H1 Receptor Antagonists

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Histamine H1 Receptor Antagonists

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Histamine H1 receptor antagonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/HB749D7580D4EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HB749D7580D4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970